Dr. Mitchell and the multi- site key personnel will be responsible for informed patient consent enrollment of subjects for this investigation. Dr. Gururangan will ensure the informed consent of procedures involving induction chemotherapy and HDC + PBCT, and Dr. Mitchell will ensure the informed consent of experimental immunotherapy consisting of DC + xALT therapy. Dr. Mitchell and his group will be responsible for all experimental procedures involving gen eration, quality assurance and quality control assessment, and administration of DC + xALT therapy in patients with reMB/PNETs. Drs. Grant and Gururangan will be Re-MATC H Protocol Page 101 of 106 Version: 20180628 responsible for the provision of neurosurgical and adjuvant chemotherapy respectively accordin g to current practice guidelines. No deviation from standard of care provision of therapy other than the addition of immunotherapy is mandated by enrollment on this protocol . During admission to the BMT unit, HDC + PBSCT will be provided by the local primary team with Dr. Mitchell coordinating the interaction between these treating physicians and the research study team.